BriaCell Therapeutics Corp. (BCTX) Stock

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is led by CEO William V. Williams, employs 16 people, headquartered in CA, publicly traded since 2012.

BriaCell Therapeutics Corp. (BCTX) stock trades at $3.44 with a market capitalization of $29.88M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.33, reflecting a net loss over the last twelve months, price-to-book of 1.22, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.60 and $14.68, and currently trades 76.6% below its 52-week high.

On profitability, BriaCell Therapeutics Corp. generates a return on equity (ROE) of -147.92% (negative, reflecting a net loss), return on capital employed of -136.31%.

BriaCell Therapeutics Corp. by the numbers, 2016–2025

Between 2016 and 2025 BriaCell Therapeutics Corp. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-36.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-36.0M.

Borrowings stand at $0, cash from operations was $-39.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 50.5% over five years, and was -144.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BriaCell Therapeutics Corp. (BCTX) — frequently asked questions